Breast cancer is the most commonly diagnosed cancer in American women with 209,060 and 54,010 estimated cases of invasive breast cancer and female carcinoma in situ, respectively, in 2010. Approximately 39,840 women will die of breast cancer in the United States in 2010.1Risk factors for the development of breast cancer can be grouped into categories, including familial/genetic factors (family history, known or suspected BRCA1/2, TP53, PTEN, or other gene mutation associated with breast cancer risk); factors related to demographics (e.g., age, ethnicity/race); reproductive history (age at menarche, parity, age at first live birth, age at menopause); environmental factors (prior thoracic irradiation before age 30 years [e.g., to treat Hodgkin disease], hormone replacement therapy [HRT], alcohol consumption); and other factors (e.g., number of breast biopsies, atypical hyperplasia or lobular carcinoma in situ [LCIS], breast density, body mass index).Estimating breast cancer risk for the individual woman is difficult, and most breast cancers are not attributable to risk factors other than female gender and increased age. The development of effective strategies for the reduction of breast cancer incidence has also been difficult because few of the existing risk factors are modifiable and some of the potentially modifiable risk factors have social implications extending beyond concerns for breast cancer (e.g., age at first live birth). Nevertheless, effective breast cancer risk reduction agents/strategies, such as tamoxifen, raloxifene, and risk reduction surgery, have been identified. However, women and their physicians who are considering interventions to reduce risk for breast cancer must balance the demonstrated...
  • 1.

    JemalASiegelRXuJWardE. Cancer statistics, 2010. CA Cancer J Clin2010;60:277300.

  • 2.

    MurffHJByrneDSyngalS. Cancer risk assessment: quality and impact of the family history interview. Am J Prev Med2004;27:239245.

  • 3.

    MurffHJSpigelDRSyngalS. Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA2004;292:14801489.

    • Search Google Scholar
    • Export Citation
  • 4.

    ColditzGAWillettWCHunterDJ. Family history, age, and risk of breast cancer. Prospective data from the Nurses' Health Study. JAMA1993;270:338343.

    • Search Google Scholar
    • Export Citation
  • 5.

    SlatteryMLKerberRA. A comprehensive evaluation of family history and breast cancer risk. The Utah Population Database. JAMA1993;270:15631568.

    • Search Google Scholar
    • Export Citation
  • 6.

    LynchHTWatsonPConwayTALynchJF. Clinical/genetic features in hereditary breast cancer. Breast Cancer Res Treat1990;15:6371.

  • 7.

    PharoadPDDayNEDuffyS. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer1997;71:800809.

    • Search Google Scholar
    • Export Citation
  • 8.

    BerlinerJLFayAM. Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors. J Genet Couns2007;16:241260.

    • Search Google Scholar
    • Export Citation
  • 9.

    FoulkesWD. Inherited susceptibility to common cancers. N Engl J Med2008;359:21432153.

  • 10.

    TrepanierAAhrensMMcKinnonW. Genetic cancer risk assessment and counseling: recommendations of the National Society of Genetic Counselors. J Genet Couns2004;13:83114.

    • Search Google Scholar
    • Export Citation
  • 11.

    PharoahPDAntoniouABobrowM. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet2002;31:3336.

  • 12.

    ParmigianiGBerryDAAguilarO. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet1998;62:145158.

    • Search Google Scholar
    • Export Citation
  • 13.

    AntoniouACCunninghamAPPetoJ. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer2008;98:14571466.

    • Search Google Scholar
    • Export Citation
  • 14.

    TyrerJDuffySWCuzickJ. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med2004;23:11111130.

  • 15.

    AmirEEvansDGShentonA. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet2003;40:807814.

    • Search Google Scholar
    • Export Citation
  • 16.

    ClausEBRischNThompsonWD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer1994;73:643651.

    • Search Google Scholar
    • Export Citation
  • 17.

    EvansDGHowellA. Breast cancer risk-assessment models. Breast Cancer Res2007;9:213.

  • 18.

    SaslowDBoetesCBurkeW. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin2007;57;7589.

    • Search Google Scholar
    • Export Citation
  • 19.

    GreendaleGAReboussinBASloneS. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst2003;95:3037.

  • 20.

    ChiuSYDuffySYenAM. Effect of baseline breast density on breast cancer incidence, stage, mortality, and screening parameters: 25-year follow-up of a Swedish mammographic screening. Cancer Epidemiol Biomarkers Prev2010;19:12191228.

    • Search Google Scholar
    • Export Citation
  • 21.

    VachonCMSellersTAScottCG. Longitudinal breast density and risk of breast cancer [abstract]. Presented at the American Association for Cancer Research 101st Annual Meeting; April 17–21 2010; Washington DC. Abstract 4828.

    • Search Google Scholar
    • Export Citation
  • 22.

    GailMHBrintonLAByarDP. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst1989;81:18791886.

    • Search Google Scholar
    • Export Citation
  • 23.

    SpiegelmanDColditzGAHunterD. Validation of the Gail model for predicting individual breast cancer risk. J Natl Cancer Inst1994;86:600607.

    • Search Google Scholar
    • Export Citation
  • 24.

    CostantinoJPGailMHPeeM. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst1999;91:15411548.

    • Search Google Scholar
    • Export Citation
  • 25.

    RockhillBSpiegelmanDByrneC. Validation of the Gail model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst2001;93:358366.

    • Search Google Scholar
    • Export Citation
  • 26.

    GailMHCostantinoJP. Validating and improving models for projecting the absolute risk of breast cancer. J Natl Cancer Inst2001;93:334335.

    • Search Google Scholar
    • Export Citation
  • 27.

    FisherBCostantinoJPWickerhamDL. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst1998;90:13711388.

    • Search Google Scholar
    • Export Citation
  • 28.

    VogelVGCostantinoJPWickerhamDL. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA2006;295:27272741.

    • Search Google Scholar
    • Export Citation
  • 29.

    VogelVGCostantionoJPWickerhamDL. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res2010;2:696706.

    • Search Google Scholar
    • Export Citation
  • 30.

    GailMHCostantinoJPPeeD. Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst2007;99:17821792.

    • Search Google Scholar
    • Export Citation
  • 31.

    BhatiaSRobisonLLOberlinO. Breast cancer in patients irradiated for Hodgkin's disease: a clinical and pathologic analysis of 45 events in 37 patients. J Clin Oncol1992;10:16741681.

    • Search Google Scholar
    • Export Citation
  • 32.

    BhatiaSYasuiYRobisonLL. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol2003;21:43864394.

    • Search Google Scholar
    • Export Citation
  • 33.

    TravisLBHillDDoresGM. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst2005;97:14281437.

    • Search Google Scholar
    • Export Citation
  • 34.

    YahalomJPetrekJABiddingerPW. Breast cancer in patients irradiated for Hodgkin's disease: a clinical and pathologic analysis of 45 events in 37 patients. J Clin Oncol1992;10:16741681.

    • Search Google Scholar
    • Export Citation
  • 35.

    HancockSLTuckerMAHoppeRT. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst1993;85:2531.

  • 36.

    HudsonMMPoquetteCALeeJ. Increased mortality after successful treatment for Hodgkin's disease. J Clin Oncol1998;16:35923600.

  • 37.

    van LeeuwenFEKlokmanWJStovallM. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst2003;95:971980.

    • Search Google Scholar
    • Export Citation
  • 38.

    RosenPPKosloffCLiebermanPH. Lobular carcinoma in situ of the breast. Detailed analysis of 99 patients with average follow-up of 24 years. Am J Surg Pathol1978;2:225251.

    • Search Google Scholar
    • Export Citation
  • 39.

    HaagensenCDBodianCHaagensenDEJr. Breast Carcinoma: Risk and Detection. Philadelphia, PA: W.B. Saunders: 1981.

  • 40.

    FordDEastonDFStrattonM. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet1998;62:676689.

    • Search Google Scholar
    • Export Citation
  • 41.

    AntoniouACPharoahPDEastonDF. BRCA1 and BRCA2 cancer risks. J Clin Oncol2006;24:33123313; author reply 3313–3314.

  • 42.

    StruewingJPHartgePWacholderS. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med1997;336:14011408.

    • Search Google Scholar
    • Export Citation
  • 43.

    KingMCMarksJHMandellJB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science2003;302:643646.

  • 44.

    HartmannLCSchaidDJWoodsJE. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med1999;340:7784.

    • Search Google Scholar
    • Export Citation
  • 45.

    HartmannLCSellersTASchaidDJ. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst2001;93:16331637.

    • Search Google Scholar
    • Export Citation
  • 46.

    HammRMLawlerFScheidD. Prophylactic mastectomy in women with a high risk of breast cancer. N Engl J Med1999;340:18371839.

  • 47.

    Meijers-HeijboerHvan GeelBvan PuttenWL. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med2001;345:159164.

    • Search Google Scholar
    • Export Citation
  • 48.

    RebbeckTRFriebelTLynchHT. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol2004;22:10551062.

    • Search Google Scholar
    • Export Citation
  • 49.

    BougheyJCKhakpourNMeric-BernstamF. Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer2006;107:14401447.

    • Search Google Scholar
    • Export Citation
  • 50.

    Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer2000;83:13011308.

    • Search Google Scholar
    • Export Citation
  • 51.

    AntoniouAPharoahPDNarodS. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet2003;72:11171130.

    • Search Google Scholar
    • Export Citation
  • 52.

    SatagoganJMBoydJKnaffND. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res2002;8:37763781.

    • Search Google Scholar
    • Export Citation
  • 53.

    RebbeckTRLynchHTNeuhausenSL. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med2002;346:16161622.

  • 54.

    RebbeckTRKauffNDDomchekSM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst2009;101:8087.

    • Search Google Scholar
    • Export Citation
  • 55.

    KauffNDSatagopanJMRobsonME. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med2002;346:16091615.

    • Search Google Scholar
    • Export Citation
  • 56.

    FinchABeinerMLubinskiJ. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA2006;296:185192.

    • Search Google Scholar
    • Export Citation
  • 57.

    KemelY KNRobsonMEGoldfrankDJ. Four year follow-up of outcomes following risk-reducing salpingo-oophorectomy in BRCA mutation carriers [abstract]. J Clin Oncol2005;23(Suppl 1):Abstract 1013.

    • Search Google Scholar
    • Export Citation
  • 58.

    RebbeckTRLevinAMEisenA. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst1999;91:14751479.

    • Search Google Scholar
    • Export Citation
  • 59.

    EisenALubinskiJKlijnJ. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol2005;23:74917496.

    • Search Google Scholar
    • Export Citation
  • 60.

    KnaffNDDomchekSMFriebelTM. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol2008;26:13311337.

    • Search Google Scholar
    • Export Citation
  • 61.

    KurianAWSigalBMPlevritisSK. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol2010;28:222231.

    • Search Google Scholar
    • Export Citation
  • 62.

    Report from the Breast Cancer Trials Committee Scottish Cancer Trials Office (MRC) Edinburgh. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Lancet1987;2:171175.

    • Search Google Scholar
    • Export Citation
  • 63.

    Preliminary analysis by the CRC Adjuvant Breast Trial Working Party. Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. Br J Cancer1988;57:604607.

    • Search Google Scholar
    • Export Citation
  • 64.

    FisherBCostantinoJRedmondC. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med1989;320:479484.

    • Search Google Scholar
    • Export Citation
  • 65.

    RutqvistLECedermarkBGlasU. Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J Natl Cancer Inst1991;83:12991306.

    • Search Google Scholar
    • Export Citation
  • 66.

    Early Breast Cancer Trialists' Collaborative Group (EBCCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet2005;365:16871717.

    • Search Google Scholar
    • Export Citation
  • 67.

    FisherBCostantinoJPWickerhamDL. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst2005;97:16521662.

    • Search Google Scholar
    • Export Citation
  • 68.

    KingMCWieandSHaleK. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA2001;286:22512256.

    • Search Google Scholar
    • Export Citation
  • 69.

    Tamoxifen [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals; 2006.

  • 70.

    PowlesTEelesRAshleyS. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet1998;352:98101.

    • Search Google Scholar
    • Export Citation
  • 71.

    CuzickJPowlesTVeronesiU. Overview of the main outcomes in breast-cancer prevention trials. Lancet2003;361:296300.

  • 72.

    PowlesTJSahleySTidyA. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst2007;99:283290.

    • Search Google Scholar
    • Export Citation
  • 73.

    VeronesiUMaisonneuvePCostaA. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet1998;352:9397.

    • Search Google Scholar
    • Export Citation
  • 74.

    VeronesiUMaisonneuvePSacchiniV. Tamoxifen for breast cancer among hysterectomised women. Lancet2002;359:11221124.

  • 75.

    VeronesiUMaisonneuvePRotmenszN. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst2007;99:727737.

    • Search Google Scholar
    • Export Citation
  • 76.

    VeronesiUMaisonneuvePRotmenszN. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst2003;95:160165.

    • Search Google Scholar
    • Export Citation
  • 77.

    BeversTB. Breast cancer chemoprevention: current clinical practice and future direction. Biomed Pharmacother2001;55:559564.

  • 78.

    CuzickJForbesJEdwardsR. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet2002;360:817824.

    • Search Google Scholar
    • Export Citation
  • 79.

    CuzickJForbesJFSestakI. Long-term results of tamoxifen prophylaxis for breast cancer—96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst2007;99:272282.

    • Search Google Scholar
    • Export Citation
  • 80.

    DecensiAGandiniSSerranoD. Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users. J Clin Oncol2007;25:42014209.

    • Search Google Scholar
    • Export Citation
  • 81.

    SiderasKIngleJNAmesMM. Coprescription of tamoxifen and medications that inhibit CYP2D6. J Clin Oncol2010;28:27682776.

  • 82.

    LashTRosenbergCL. Evidence and practice regarding the role of CYP2D6 inhibition in decisions about tamoxifen therapy. J Clin Oncol2010;28:12731275.

    • Search Google Scholar
    • Export Citation
  • 83.

    HigginsMJStearnsV. CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep2010;12:715.

  • 84.

    Raloxifene (Evista) [package insert]. Indianapolis, IN: Eli Lilly and Company; 2007.

  • 85.

    EttingerBBlackDMMitlakBH. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA1999;282:637645.

    • Search Google Scholar
    • Export Citation
  • 86.

    CummingsSREckertSKruegerKA. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA1999;281:21892197.

    • Search Google Scholar
    • Export Citation
  • 87.

    MartinoSCauleyJABarrett-ConnorE. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst2004;96:17511761.

    • Search Google Scholar
    • Export Citation
  • 88.

    Barrett-ConnorEMoscaLCollinsP. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med2006;355:125137.

    • Search Google Scholar
    • Export Citation
  • 89.

    GradyDCauleyJAGeigerMJ. Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk. J Natl Cancer Inst2008;100:854861.

    • Search Google Scholar
    • Export Citation
  • 90.

    LandSRWickerhamDLCostantinoJP. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA2006;295:27422751.

    • Search Google Scholar
    • Export Citation
  • 91.

    BaumMBudzarAUCuzickJ. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet2002;359:21312139.

    • Search Google Scholar
    • Export Citation
  • 92.

    BaumMBuzdarACuzickJ. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer2003;98:18021810.

    • Search Google Scholar
    • Export Citation
  • 93.

    CoombesRCHallEGibsonLJ. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med2004;350:10811092.

    • Search Google Scholar
    • Export Citation
  • 94.

    GossPEIngleJNMartinoS. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med2003;349:17931802.

    • Search Google Scholar
    • Export Citation
  • 95.

    ThurlimannBKeshaviahACoatesAS. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med2005;353:27472757.

    • Search Google Scholar
    • Export Citation
  • 96.

    RichardsonHJohnstonDPaterJ. The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial. An international breast cancer prevention trial. Curr Oncol2007;14:8996.

    • Search Google Scholar
    • Export Citation
  • 97.

    CuzickJ. IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. Expert Rev Anticancer Ther2008;8:13771385.

    • Search Google Scholar
    • Export Citation
  • 98.

    CurtinJKavanaghJ. Corpus: mesenchymal tumors. In: HoskinsWPerezCYoungR eds. Principles and Practice of Gynecologic Oncology 3rd ed.Philadelphia, PA: Lippincott Williams & Wilkins; 2000:961979.

    • Search Google Scholar
    • Export Citation
  • 99.

    BergmanLBeelenMLGalleeMP. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet2000;356:881887.

    • Search Google Scholar
    • Export Citation
  • 100.

    CurtisREFreedmanDMShermanMEFraumeniJFJr. Risk of malignant mixed müllerian tumors after tamoxifen therapy for breast cancer. J Natl Cancer Inst2004;96:7074.

    • Search Google Scholar
    • Export Citation
  • 101.

    Nolvadex [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals; 2006.

  • 102.

    BouchardyCVerkooijenHMFiorettaG. Increased risk of malignant müllerian tumor of the uterus among women with breast cancer treated by tamoxifen. J Clin Oncol2002;20:4403.

    • Search Google Scholar
    • Export Citation
  • 103.

    RieckGCFreitesONWilliamsS. Is tamoxifen associated with high-risk endometrial carcinomas? A retrospective case series of 196 women with endometrial cancer. J Obstet Gynaecol2005;25:3941.

    • Search Google Scholar
    • Export Citation
  • 104.

    WysowskiDKHonigSFBeitzJ. Uterine sarcoma associated with tamoxifen use. N Engl J Med2002;346:18321833.

  • 105.

    ACOG Committee Opinion. No. 336: Tamoxifen and uterine cancer. American College of Obstetrics and Gynecology Committee on Gynecologic Practice. Obstet Gynecol2006;107:14741478.

    • Search Google Scholar
    • Export Citation
  • 106.

    FungMFReidAFaughtW. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen. Gynecol Oncol2003;91:154159.

    • Search Google Scholar
    • Export Citation
  • 107.

    BarakatRRGilewskiTAAlmadronesL. Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy. J Clin Oncol2000;18:34593463.

    • Search Google Scholar
    • Export Citation
  • 108.

    GerberBKrauseAMullerH. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. J Clin Oncol2000;18:34643470.

    • Search Google Scholar
    • Export Citation
  • 109.

    NayfieldSGGorinMB. Tamoxifen-associated eye disease. A review. J Clin Oncol1996;14:10181026.

  • 110.

    GorinMBCostantinoJPKulacogluDN. Is tamoxifen a risk factor for retinal vaso-occlusive disease?Retina2005;25:523526.

  • 111.

    GradyDEttingerBMoscarelliE. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet Gynecol2004;104:837844.

    • Search Google Scholar
    • Export Citation
  • 112.

    SverrisdottirAFornanderTJacobssonH. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol2004;22:36943699.

    • Search Google Scholar
    • Export Citation
  • 113.

    VehmanenLElomaaIBlomqvistCSaartoT. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol2006;24:675680.

    • Search Google Scholar
    • Export Citation
  • 114.

    PowlesTJHIckishTKanisJA. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy women. J Clin Oncol1996;14:7884.

    • Search Google Scholar
    • Export Citation
  • 115.

    DecensiAMaisonneuvePRotmenszN. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation2005;111:650656.

    • Search Google Scholar
    • Export Citation
  • 116.

    BushnellCDGoldsteinLB. Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis. Neurology2004;63:12301233.

    • Search Google Scholar
    • Export Citation
  • 117.

    BraithwaiteRSChlebowskiRTLauJ. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med2003;18:937947.

    • Search Google Scholar
    • Export Citation
  • 118.

    AbramsonNCostantinoJPGarberJE. Effect of Factor V Leiden and prothrombin G20210→A mutations on thromboembolic risk in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial. J Natl Cancer Inst2006;98:904910.

    • Search Google Scholar
    • Export Citation
  • 119.

    GuttusoTJJr. Gabapentin's effects on hot flashes and hypothermia. Neurology2000;54:21612163.

  • 120.

    LoprinziLBartonDLSloanJA. Pilot evaluation of gabapentin for treating hot flashes. Mayo Clin Proc2002;77:11591163.

  • 121.

    GuttusoTJrKurlanRMcDermottMPKieburtzK. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol2003;101:337345.

    • Search Google Scholar
    • Export Citation
  • 122.

    PandyaKJMorrowGRRoscoeJA. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet2005;366:818824.

    • Search Google Scholar
    • Export Citation
  • 123.

    LoprinziCLKuglerJWSloanJA. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized controlled trial. Lancet2000;356:20592063.

    • Search Google Scholar
    • Export Citation
  • 124.

    StearnsVBeebeKLIyengarMDubeE. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA2003;289:28272834.

    • Search Google Scholar
    • Export Citation
  • 125.

    StearnsVSlackRGreepN. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol2005;23:69196930.

    • Search Google Scholar
    • Export Citation
  • 126.

    JinYDestaZStearnsV. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst2005;97:3039.

    • Search Google Scholar
    • Export Citation
  • 127.

    MortimerJEFlattSWParkerBA. Tamoxifen, hot flashes and recurrence of breast cancer. Breast Cancer Res Treat2008;108:421426.

  • 128.

    OsborneCRDuncanASedlacekS. The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer. Breast Cancer Res Treat2009;116:521527.

    • Search Google Scholar
    • Export Citation
  • 129.

    NelsonHDVescoKKHaneyE. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA2006;295:20572071.

    • Search Google Scholar
    • Export Citation
  • 130.

    LauferLRErlikYMeldrumDRJuddHL. Effect of clonidine on hot flashes in postmenopausal women. Obstet Gynecol1982;60:583586.

  • 131.

    NagamaniMKelverMESmithER. Treatment of menopausal hot flashes with transdermal administration of clonidine. Am J Obstet Gynecol1987;156:561565.

    • Search Google Scholar
    • Export Citation
  • 132.

    GoldbergRMLoprinziCLO'FallonJR. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol1994;12:155158.

  • 133.

    BartonDLLoprinziCLQuellaSK. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol1998;16:495500.

    • Search Google Scholar
    • Export Citation
  • 134.

    PockajBAGallagherJGLoprinziCL. Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1. J Clin Oncol2006;24:28362841.

    • Search Google Scholar
    • Export Citation
  • 135.

    CarpenterJS. Hot flashes and their management in breast cancer. Semin Oncol Nurs2000;16:214225.

  • 136.

    FallowfieldLJBlissJMPorterLS. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol2006;24:910917.

    • Search Google Scholar
    • Export Citation
  • 137.

    MahoneyMC. Breast cancer risk reduction and counseling: lifestyle, chemoprevention, and surgery. J Natl Compr Canc Netw2007;5:702710.

    • Search Google Scholar
    • Export Citation
  • 138.

    VisvanathanKChlebowskiRTHurleyP. American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol2009;27:32353258.

    • Search Google Scholar
    • Export Citation
  • 139.

    O'ReganRMGajdosCDardesRC. Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice. J Natl Cancer Inst2002;94:274283.

    • Search Google Scholar
    • Export Citation
  • 140.

    van DijkSvan RoosmalenMOttenWStalmeierPFM. Decision making regarding prophylactic mastectomy: stability of preferences and the impact of anticipated feelings of regret. J Clin Oncol2008;26:23582363.

    • Search Google Scholar
    • Export Citation
  • 141.

    PatneaudeAFOrozcoSLiX. Support needs and acceptability of psychological and peer consultation: attitudes of 108 women who had undergone or were considering prophylactic mastectomy. Psychooncology2008;17:831843.

    • Search Google Scholar
    • Export Citation
  • 142.

    BresserPJCVan GoolARSeynaeveC. Who is prone to high levels of distress after prophylactic mastectomy and/or salpingo-ovariectomy?Ann Oncol2007;18:16411645.

    • Search Google Scholar
    • Export Citation
  • 143.

    GiulianoAEBoolbolSDegnimA. Society of Surgical Oncology: position statement on prophylactic mastectomy. Approved by the Society of Surgical Oncology Executive Council, March 2007. Ann Surg Oncol2007;14:24252427.

    • Search Google Scholar
    • Export Citation
  • 144.

    MorrowMMehraraB. Prophylactic mastectomy and the timing of breast reconstruction. Br J Surg2009;96:12.

  • 145.

    RebbeckTRFriebelTWagnerT. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol2005;23:78047810.

    • Search Google Scholar
    • Export Citation
  • 146.

    EisenALubinskiJGronwaldJ. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst2008;100:13611367.

    • Search Google Scholar
    • Export Citation
  • 147.

    GarberJEHartmanAR. Prophylactic oophorectomy and hormone replacement therapy: protection at what price?J Clin Oncol2004;22:978980.

  • 148.

    ChlebowskiRTPrenticeRL. Menopausal hormone therapy in BRCA1 mutation carriers: uncertainty and caution. J Natl Cancer Inst2008:100:13411342.

    • Search Google Scholar
    • Export Citation
  • 149.

    GrannVRJacobsonJSThomasonD. Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. J Clin Oncol2002;20:25202529.

    • Search Google Scholar
    • Export Citation
  • 150.

    MahoneyMCBeversTLinosEWillettWC. Opportunities and strategies for breast cancer prevention through risk reduction. CA Cancer J Clin2008;58:347371.

    • Search Google Scholar
    • Export Citation
  • 151.

    RossouwJEAndersonGLPrenticeRL. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA2002;288:321333.

    • Search Google Scholar
    • Export Citation
  • 152.

    AndersonGLLimacherMAssafAR. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;29117011712.

    • Search Google Scholar
    • Export Citation
  • 153.

    AndersonGLChlebowskiRTRossouwJE. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas2006;55:103105.

    • Search Google Scholar
    • Export Citation
  • 154.

    ChlebowskiRTKullerLHPrenticeRL. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl Med2009;360:573587.

    • Search Google Scholar
    • Export Citation
  • 155.

    StefanickMLAndersonGLMargolisKL. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA2006;295:16471657.

    • Search Google Scholar
    • Export Citation
  • 156.

    RohanTENegassaAChlebowskiRT. Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial. J Natl Cancer Inst2008;100:563571.

    • Search Google Scholar
    • Export Citation
  • 157.

    McTiernanAChlebowskiRTMartinC. Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the Women's Health Initiative Randomized Trial. J Clin Oncol2009;27:61356143.

    • Search Google Scholar
    • Export Citation
  • 158.

    McTiernanAMartinCFPeckJD. Estrogen-plus-progestin use and mammographic density in postmenopausal women: women's health initiative randomized trial. J Natl Cancer Inst2005;97:13661376.

    • Search Google Scholar
    • Export Citation
  • 159.

    RosenbergLPalmerJRWiseLAAdams-CampbellLL. A prospective study of female hormone use and breast cancer among black women. Arch Intern Med2006;166:760765.

    • Search Google Scholar
    • Export Citation
  • 160.

    BeralV. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet2003;362:419427.

  • 161.

    ChenWYMansonJEHankinsonSE. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med2006;166:10271032.

  • 162.

    SantenRJAllredDC. The estrogen paradox. Nat Clin Pract Endocrinol Metab2007;3:496497.

  • 163.

    RossouwJEPrenticeRLMansonJE. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA2007;297:14651477.

    • Search Google Scholar
    • Export Citation
  • 164.

    FornierAMesrineSBoutron-RuaultMCClavel-ChapelonF. Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?J Clin Oncol2009;27:51385143.

    • Search Google Scholar
    • Export Citation
  • 165.

    TerryMBZhangFFKabatG. Lifetime alcohol intake and breast cancer risk. Ann Epidemiol2006;16:230240.

  • 166.

    SuzukiRYeWRylander-RudqvistT. Alcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: a prospective cohort study. J Natl Cancer Inst2005;97:16011608.

    • Search Google Scholar
    • Export Citation
  • 167.

    HowardRALeitzmannMFLinetMSFreedmanDM. Physical activity and breast cancer risk among pre- and postmenopausal women in the U.S. Radiologic Technologists Cohort. Cancer Causes Control2009;20:323333.

    • Search Google Scholar
    • Export Citation
  • 168.

    LahmannPHFriedenreichCSchuitAJ. Physical activity and breast cancer risk: the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev2007;16:3642.

    • Search Google Scholar
    • Export Citation
  • 169.

    TehardBFriedenreichCMOppertJMClavel-ChapelonF. Effect of physical activity on women at increased risk of breast cancer: results from the E3N cohort study. Cancer Epidemiol Biomarkers Prev2006;15:5764.

    • Search Google Scholar
    • Export Citation
  • 170.

    BernsteinLPatelAVUrsinG. Lifetime recreational exercise activity and breast cancer risk among black women and white women. J Natl Cancer Inst2005;97:16711679.

    • Search Google Scholar
    • Export Citation
  • 171.

    FriedenreichCMWoolcottCGMcTiernanA. Alberta physical activity and breast cancer prevention trial: sex hormone changes in a year-long exercise intervention among postmenopausal women. J Clin Oncol2010;28:14581466.

    • Search Google Scholar
    • Export Citation
  • 172.

    ChlebowskiRT. Lifestyle and breast cancer risk: the way forward?J Clin Oncol2010;28:14551457.

  • 173.

    PrenticeRLCaanBChlebowskiRT. Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative randomized controlled dietary modification trial. JAMA2006;295:629642.

    • Search Google Scholar
    • Export Citation
  • 174.

    MichelsKBWillettWC. The Women's Health Initiative randomized controlled dietary modification trial: a post-mortem. Breast Cancer Res Treat2009:114:16.

    • Search Google Scholar
    • Export Citation
  • 175.

    LinosEWillettWC. Diet and breast cancer risk. J Natl Compr Canc Netw2007;5:711718.

  • 176.

    TrettiSGaardM. Lifestyle changes during adolescence and risk of breast cancer: an ecologic study of the effect of World War II in Norway. Cancer Causes Control1996;7:507512.

    • Search Google Scholar
    • Export Citation
  • 177.

    HuFBWilletWC. Optimal diets for prevention of coronary heart disease. JAMA2002;288:25692578.

  • 178.

    Bertone-JohnsonERChenWYHolickMF. Plasma 25-hydroxyvitamin D, and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev2005;14:19911997.

    • Search Google Scholar
    • Export Citation
  • 179.

    KnightJALesoskyMBarnettH. Vitamin D and reduced risk of breast cancer: a population-based case-control study. Cancer Epidemiol Biomarkers Prev2007;16:422429.

    • Search Google Scholar
    • Export Citation
  • 180.

    BlackmoreKMLesoskyMBarnettH. Vitamin D from dietary intake and sunlight exposure and the risk of hormone-receptor-defined breast cancer. Am J Epidemiol2008;168:915924.

    • Search Google Scholar
    • Export Citation
  • 181.

    EliassenAHColkditzGARosnerB. Adult weight change and risk of postmenopausal breast cancer. JAMA2006;296:193201.

  • 182.

    KotsopoulosJOlopadoOIGhadirianP. Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res2005;7:R833843.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 195 196 13
PDF Downloads 39 39 1
EPUB Downloads 0 0 0